The artificial sweetener erythritol and cardiovascular event riskMarco Witkowski, Stanley L. Hazen, Ilja Demuth et al.|Nature Medicine|2023Cited by 205
Gut Microbiota-Generated Phenylacetylglutamine and Heart FailureKymberleigh A. Romano, Stanley L. Hazen, Ina Nemet et al.|Circulation Heart Failure|2022Cited by 150
A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease riskMarc Ferrell, Stanley L. Hazen, Zeneng Wang et al.|Nature Medicine|2024Cited by 124
Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortalityIna Nemet, Stanley L. Hazen, Xinmin S. Li et al.|European Heart Journal|2023Cited by 120
Prognostic Value of Gut Microbe-Generated Metabolite Phenylacetylglutamine in Patients with Heart FailureW.H. Wilson Tang, Stanley L. Hazen, Ina Nemet et al.|European Journal of Heart Failure|2023Cited by 38